Role of phytate and osteopontin in the mechanism of soft tissue calcification

Journal of Nephrology

Volumn 21, Issue 5, 2008, Pages 768-775

  Grases, Félix ^a,b   Prieto, Rafel M ^a,b   Sanchis, Pilar ^a   Saus, Carles ^c   de Francisco, Teresa ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Osteopontin; Phytate; Soft tissue calcification

Indexed keywords

CALCIUM; HYDROXYAPATITE; OSTEOPONTIN; PERMANGANATE POTASSIUM; PHYTATE; PHYTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCINOSIS; CONTROLLED STUDY; CRYSTALLIZATION; DIET THERAPY; DISEASE ASSOCIATION; HISTOPATHOLOGY; INFLAMMATION; MALE; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; RAT; SOFT TISSUE CALCIFICATION; ANIMAL; EOSINOPHIL; LYMPHOCYTE; MACROPHAGE; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; CALCINOSIS; CALCIUM; EOSINOPHILS; INFLAMMATION; LYMPHOCYTES; MACROPHAGES; MALE; OSTEOPONTIN; PHYTIC ACID; RATS; RATS, WISTAR;

EID: 63249133253     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Brancaccio D, Cozzolino M. The mechanism of calcium deposition in soft tissues. Contrib Nephrol. 2005;149:279-286.
2. Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI, O'Neill WC. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol. 2004;15:1392-1401.
3. Fleisch H, Bisaz S. Mechanism of calcification: inhibitory role of pyrophosphate. Nature. 1962;195:911.
4. Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M. Bisphosphonates and atherosclerosis: why? Lupus. 2005;14:773-779.
5. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001;21:817-824.
6. Price PA, Buckley JR, Williamson MK. The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr. 2001;131:2910-2915.
7. Grases F, Sanchis P, Perello J, et al. Phytate (myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats. Front Biosci. 2006;11:136-142.
8. Grases F, Sanchis P, Perelló J, et al. Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: a pilot study in Sprague-Dawley rats. Circ J. 2007;71:1152-1156.
9. Grases F, Simonet BM, Prieto RM, March JG. Variation of InsP4, InsP5 and InsP6 levels in tissues and biological fluids depending on dietary phytate. J Nutr Biochem. 2001;12:595-601.
10. Grases F, Simonet BM, Vucenik I, et al. Absorption and excretion of orally administered inositol hexaphosphate (IP6 or phytate) in humans. Biofactors. 2001;15:53-61.
11. Bas A, Lopez I, Perez J, Rodriguez M, Aguilera-Tejero E. Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res. 2006;21:484-490.
12. Redey SA, Razzouk S, Rey C, et al. Osteoclast adhesion and activity on synthetic hydroxyapatite, carbonated hydroxyapatite, and natural calcium carbonate: relationship to surface energies. J Biomed Mater Res. 1999;45:140-147.
13. Shen M, Marie P, Farge D, et al. Osteopontin is associated with bioprosthetic heart valve calcification in humans. C R Acad Sci III. 1997;320:49-57.
14. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92:1686-1696.
15. O'Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is expressed in human aortic valvular lesions. Circulation. 1995;92:2163-2168.
16. Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin-a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A. 1990;87:4473-4475.
17. Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A. 1999;96:8156-8160.
18. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268.
19. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
20. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139:1329-1337.
21. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78-81.
22. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol. 1998;18:1400-1407.
23. Zebboudj AF, Imura M, Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem. 2002;277:4388-4394.
24. Levy RJ, Schoen FJ, Levy JT, Nelson AC, Howard SL, Oshry LJ. Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats. Am J Pathol. 1983;113:143-155.
25. Boskey AL, Maresca M, Ullrich W, Doty SB, Butler WT, Prince CW. Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner. 1993;22:147-159.
26. Hunter GK, Goldberg HA. Nucleation of hydroxyapatite by bone sialoprotein. Proc Natl Acad Sci U S A. 1993;90:8562-8565.
27. Hunter GK, Haushka PV, Poole AR, Rosenberg LC, Goldberg HA. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J. 1996;317:59-64.
28. Govindaraj A, Selvam R. An oxalate-binding protein with crystal growth promoter activity from human kidney stone matrix. BJU Int. 2002;90:336-344.
29. Lieske JC, Toback FG, Deganello S. Sialic acid-containing glycoproteins on renal cells determine nucleation of calcium oxalate dihydrate crystals. Kidney Int. 2001;60:1784-1791.
30. Yamate T, Kohri K, Umekawa T, et al. The effect of osteopontin on the adhesion of calcium oxalate crystals to Madin-Darby canine kidney cells. Eur Urol. 1996;30:388-393.
31. Ruoslahti E, Obrink B. Common principles in cell adhesion. Exp Cell Res. 1996;227:1-11.
32. Vignery A. Osteoclasts and giant cells: Macrophagemacrophage fusion mechanism. Int J Exp Pathol. 2000;81:291-304.
33. Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of soft tissue calcification. Am J Pathol. 2002;161:2035-2046.
34. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 2000;19:615-622.
35. Gadeau AP, Chaulet H, Daret D, Kockx M, Daniel-Lamaziere JM, Desgranges C. Time course of osteopontin, osteocalcin, and osteonectin accumulation and calcification after acute vessel wall injury. J Histochem Cytochem. 2001;49:79-86.
36. Prophet EB, Mills B, Arrington JB, Sobin LH. Laboratory methods in histotechnology. Washington, DC: American Registry of Pathology; 1992.
37. Grases F, Ramis M, Costa-Bauza A. Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization: comparison with the action of other polyphosphates. Urol Res. 2000;28:136-140.
38. Grases F, Costa-Bauzá A, March JG. Artificial simulation of the early stages of renal stone formation. Br J Urol. 1994;74:298-301.
39. Grases F, Prieto RM, Simonet BM, March JG. Phytate prevents tissue calcifications in female rats. Biofactors. 2000;11:171-177.
40. Grases F, Perello J, Prieto RM, Simonet BM, Torres JJ. Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats. Life Sci. 2004;75:11-19.
41. Grases F, Simonet BM, Prieto RM, March JG. Phytate levels in diverse rat tissues: influence of dietary phytate. Br J Nutr. 2001;86:225-231.
42. Najman S, Dordevic LJ, Savic V, Ignjatovic N, Plavsic M, Uskokovic D. Changes of HAp/PLLA biocomposites and tissue reaction after subcutaneous implantation. Facta Universitatis. 2003;10:131-134.
43. Nadra I, Mason JC, Philippidis P, et al. Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification? Circ Res. 2005;96:1248-1256.
44. Sun Y, Zeng XR, Wenger L, Cheung HS. Basic calcium phosphate crystals stimulate the endocytotic activity of cells-inhibition by anti-calcification agents. Biochem Biophys Res Commun. 2003;312:1053-1059.
45. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol. 2005;16:2495-2500.
46. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18:75-85.
47. Yun MH. Kwon Ki. High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. J Pharm Biomed Anal. 2006;40:168-172.
48. Ketteler M, Westenfeld R, Schlieper G, Brandenburg V. Pathogenesis of vascular calcification in dialysis patients. Clin Exp Nephrol. 2005;9:265-270.
49. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol. 2005;16:2495-2500.
50. Chen Y. Bal, BS, Gorski JP. Calcium and collagen binding properties of osteopontin, bone sialoprotein, and bone acidic glycoprotein-75 from bone. J Biol Chem. 1992;267:24871-24878.
51. Zhang H, Ye QH, Ren N, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:709-717.